Table 1.

Demographics, clinical characteristics, treatment, and clinical course

Demographics
Median age at presentation (range)—year	16 (15–18)
Male sex—no./total no. (%)	9/11 (82)
Race—no./total no. (%)
White	10/11 (91)
Other	1/11 (9)
History of asthma	6/11 (55)
E-cigarette reported use—no./total no. (%)
THC only	10/11 (91)
Nicotine only	8/11 (73)
Both THC and nicotine	7/11 (64)
Other (CBD, cigarette smoking)	5/11 (45)
Admission to intensive care unit—no./total no. (%)	5/11 (45)
Median length of hospital stay (range)—days	5 (2–10)
Symptoms at presentation—no./total no. (%)
Respiratory related symptom	10/11 (91)
Gastrointestinal related symptom	11/11 (100)
Constitutional symptoms	11/11 (100)
Initial laboratory results—no./total no. (%)
White blood cell count (> 11,000/μL)	7/11 (64)
C-reactive protein > 0.9 mg/dL	6/6 (100)
Erythrocyte sedimentation rate > 30 mm/h	8/8 (100)
Respiratory viral panel PCR—no./total no. (%)
Rhinovirus positive	3/11 (27)
Negative	8/11 (73)
Urine drug screen—no./total no. (%)
THC positive	10/11 (91)

PCR, polymerase chain reaction; THC, tetrahydrocannabinol; CBD, cannabidiol